We introduce quanTIseq, a method to quantify the fractions of ten immune cell types from bulk RNA-sequencing data. quanTIseq was extensively validated in blood and tumor samples using simulated, flow cytometry, and immunohistochemistry data.
quanTIseq analysis of 8000 tumor samples revealed that cytotoxic T cell infiltration is more strongly associated with the activation of the CXCR3/CXCL9 axis than with mutational load and that deconvolution-based cell scores have prognostic value in several solid cancers. Finally, we used quanTIseq to show how kinase inhibitors modulate the immune contexture and to reveal immune-cell types that underlie differential patients’ responses to checkpoint blockers.
Availability:
quanTIseq is available at
http://icbi.at/quantiseq
.
Electronic supplementary material
The online version of this article (10.1186/s13073-019-0638-6) contains supplementary material, which is available to authorized users.
The exact nature of the immune response elicited by autologous induced pluripotent stem cell (iPSC) progeny is still not well understood. Here we show in murine models that autologous iPSC-derived endothelial cells (iECs) elicit an immune response that resembles the one against a comparable somatic cell, the aortic endothelial cell (AEC). These cells exhibit long-term survival in vivo and prompt a tolerogenic contexture of intra-graft characterized by elevated IL-10 expression. In contrast, undifferentiated iPSCs elicit a very different immune response with high lymphocytic infiltration and elevated IFN-γ, granzyme-B, and perforin intra-graft. Furthermore, the clonal structure of infiltrating T cells from iEC grafts is statistically indistinguishable from that of AECs, but is different from that of undifferentiated iPSC grafts. Taken together, our results indicate that the differentiation of iPSCs results in a loss of immunogenicity and leads to the induction of tolerance, despite expected antigen expression differences between iPSC-derived versus original somatic cells.
Cancer cells and embryonic tissues share a number of cellular and
molecular properties, suggesting that induced pluripotent stem cells (iPSCs) may
be harnessed to elicit anti-tumor responses in cancer vaccines. RNA-sequencing
revealed that human and murine iPSCs express tumor-associated antigens, and we
show here a proof-of principle for using irradiated iPSCs in autologous
anti-tumor vaccines. In a prophylactic setting, iPSC vaccines prevent tumor
growth in syngeneic murine breast cancer, mesothelioma, and melanoma models. As
an adjuvant, the iPSC vaccine inhibited melanoma recurrence at the resection
site and reduced metastatic tumor load, which was associated with fewer Th17
cells and increased CD11b+GR1hi myeloid cells.
Adoptive transfer of T cells isolated from vaccine treated-tumor-bearing mice
inhibited tumor growth in unvaccinated recipients, indicating that the iPSC
vaccine promotes an antigen-specific anti-tumor T cell response. Our data
suggest a generalizable strategy for multiple types of cancer that could prove
highly valuable in clinical immunotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.